Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid M E Desar

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Cancers|October 28, 2023
Personalized Therapy of SarcomasIngrid M E Desar, Christian Rothermundt
Nederlands Tijdschrift Voor Geneeskunde|July 9, 2019
[Oncology at a glance]Karen E Oskam, Carel M M Veldhoven, Ingrid M E Desar
British Journal of Clinical Pharmacology|May 22, 2019
Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness studySander Zuidema, Ingrid M E Desar, Nielka P van Erp, et al.
Current Treatment Options in Oncology|March 9, 2018
Systemic Treatment for Adults with Synovial SarcomaIngrid M E Desar, Emmy D G Fleuren, Winette T A van der Graaf
Translational Andrology and Urology|January 28, 2016
The complexity of sunitinib dosing in renal cell cancer patientsIngrid M E Desar, Sasja F Mulder, Peter F A Mulders, et al.
Clinical Pharmacology and Therapeutics|October 23, 2023
Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant InteractionJeffrey Strik, Loek A W de Jong, Joost Sijm, et al.
British Journal of Clinical Pharmacology|November 30, 2019
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized doseKim Westerdijk, Ingrid M E Desar, Neeltje Steeghs, et al.
BMJ Open|June 4, 2020
Health-related quality Of Life <b>I</b>n patients with advanced Soft TIssue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort studyEugenie Younger, Robin L Jones, Ingrid M E Desar, et al.
Cancer Management and Research|August 31, 2016
Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedinIngrid M E Desar, Anastasia Constantinidou, Suzanne E J Kaal, et al.
The Lancet. Oncology|June 3, 2023
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an updateEline L Giraud, Bas de Lijster, Stefanie D Krens, et al.
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Cancers|October 28, 2023
Personalized Therapy of SarcomasIngrid M E Desar, Christian Rothermundt
Nederlands Tijdschrift Voor Geneeskunde|July 9, 2019
[Oncology at a glance]Karen E Oskam, Carel M M Veldhoven, Ingrid M E Desar
British Journal of Clinical Pharmacology|May 22, 2019
Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness studySander Zuidema, Ingrid M E Desar, Nielka P van Erp, et al.
Current Treatment Options in Oncology|March 9, 2018
Systemic Treatment for Adults with Synovial SarcomaIngrid M E Desar, Emmy D G Fleuren, Winette T A van der Graaf
Translational Andrology and Urology|January 28, 2016
The complexity of sunitinib dosing in renal cell cancer patientsIngrid M E Desar, Sasja F Mulder, Peter F A Mulders, et al.
Clinical Pharmacology and Therapeutics|October 23, 2023
Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant InteractionJeffrey Strik, Loek A W de Jong, Joost Sijm, et al.
British Journal of Clinical Pharmacology|November 30, 2019
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized doseKim Westerdijk, Ingrid M E Desar, Neeltje Steeghs, et al.
BMJ Open|June 4, 2020
Health-related quality Of Life <b>I</b>n patients with advanced Soft TIssue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort studyEugenie Younger, Robin L Jones, Ingrid M E Desar, et al.
Cancer Management and Research|August 31, 2016
Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedinIngrid M E Desar, Anastasia Constantinidou, Suzanne E J Kaal, et al.
The Lancet. Oncology|June 3, 2023
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an updateEline L Giraud, Bas de Lijster, Stefanie D Krens, et al.
Pageof 12